Monitoring of the intracellular activation of 5-fluorouracil to deoxyribonucleotides in HT29 human colon cell line: Application to modulation of metabolism and cytotoxicity study

Fundamental and Clinical Pharmacology

Volumn 14, Issue 2, 2000, Pages 147-154

  Ciccolini, Joseph ^a   Peillard, Laurent ^a   Aubert, Claude ^a   Formento, Patricia ^b   Milano, Gérard ^b   Catalin, Jacques ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

2' deoxyinosine; FUra; HPLC; Thymidine phosphorylase; Thymidylate synthase inhibition

Indexed keywords

DEOXYINOSINE; FLUOROURACIL; THYMIDYLATE SYNTHASE INHIBITOR;

ARTICLE; COLON CANCER; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RETENTION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL;

EID: 0034034356     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2000.tb00403.x     Document Type: Article

References (34)

1. [1] Parker W.B., Cheng Y.C., Metabolism and mechanism of action of 5-fluorouracil, Pharmacol. Ther. 48 (1990) 381-395.
2. [2] Rustum Y.M., Harstrick A., Cao S., Vanhoefer U., Yin M.B., Wilke H., Seeber S., Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors, J. Clin. Oncol. 15 (1997) 389-400.
3. [3] Sobrero A.F., Aschele C., Bertino J.R., Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation, J. Clin. Oncol. 15 (1997) 368-381.
4. [4] Heidelberger C., Danenberg P.V., Moran R.G., Fluorinated pyrimidines and their nucleosides, Adv. Enzymol. Relat. Areas Mol. Biol. 54 (1983) 58-119.
5. [5] Piper A.A., Fox R.M., Biochemical basis for the differential sensitivity of human T-and B-Lymphocyte lines to 5-fluorouracil, Cancer Res. 42 (1982) 3753-3760.
6. [6] Kent R.J., Heidelberger C., Fluorinated pyrimidines. XL. The reduction of 5-fluorouridine 5′-diphosphate by ribonucleotide reductase, Mol. Pharmacol. 8 (1972) 465-475.
7. [7] Weckbecker G., Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators, Pharmacol. Ther. 50 (1991) 367-424.
8. [8] Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L. et al., Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay, Cancer Res. 48 (1988) 589-601.
9. [9] Roberts D., An isotopic assay for thymidylate synthetase, Biochemistry 5 (1966) 3546-3548.
10. [10] Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M.A., Lassota P., Traganos F., Features of apoptotic cells measured by flow cytometry, Cytometry 13 (1992) 795-808.
11. [11] Grem J.L., Fischer P.H., Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels, Cancer Res. 46 (1986) 6191-6199.
12. [12] Grem J.L., Fischer P.H., Enhancement of 5-fluorouracil's anticancer activity by dipyridamole, Pharmacol. Ther. 40 (1989) 349-371.
13. [13] Desgranges C., Razaka G., De Clercq E., Herdewijn P., Balzarini J., Drouillet F., Bricaud H., Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice, Cancer Res. 46 (1986) 1094-1101.
14. [14] Fischel J.L., Formento P., Etienne M.C., Spector T., Milano G., Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor, Biochem. Pharmacol. 53 (1997) 1703-1709.
15. [15] Arbuck S.G., Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer, Cancer 63 (1989) 1036-1044.
16. [16] Moran R.G., Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase, Cancer 63 (1989) 1008-1012.
17. [17] Barankiewicz J., Henderson J.F., Ribose 1-phosphate metabolism in Ehrlich ascites tumor cells in vitro, Biochim. Biophys. Acta 479 (1977) 371-377.
18. [18] Barankiewicz J., Henderson J.F., Determination of ribose 1-phosphate in ascites tumor cells, Biochem. Med. Metab. Biol. 17 (1977) 45-53.
19. [19] Friedkin M., Roberts D., The enzymatic synthesis of nucleosides. II. Thymidine and related pyrimidine nucleosides, J. Biol. Chem. 207 (1954) 257-266.
20. [20] Pérignon J.L., Bories D.M., Houllier A.-M., Thuillier L., Cartier P.H., Metabolism of pyrimidine bases and nucleosides by pyrimidine-nucleoside phosphorylases in cultured human lymphoid cells, Biochim. Biophys. Acta 928 (1987) 130-136.
21. 14C into nucleic acids by Ehrlich ascites tumor cells in vitro, Cancer Res. 29 (1969) 807-811.
22. [22] Evans R.M., Laskin J.D., Hakala M.T., Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil, Cancer Res. 41 (1981) 3288-3295.
23. [23] Inaba M., Mitsuhashi J., Sawada H., Miike N., Naoe Y., Daimon A. et al., Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells, Jpn. J. Cancer Res. 87 (1996) 212-220.
24. [24] Schwartz E.L., Baptiste N., O'Connor C.J., Wadler S., Otter B.A., Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase, Cancer Res. 54 (1994) 1472-1478.
25. [25] Schwartz E.L., Baptiste N., Wadler S., Makower D., Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil, J. Biol. Chem. 270 (1995) 19073-19077.
26. [26] Evrard A., Cuq P., Robert B., Vian L., Pelegrin A., Cano J.P., Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study, Int. J. Cancer 80 (1999) 465-470.
27. [27] Evrard A., Cuq P., Ciccolini J., Vian L., Cano J.P., Increased cytotoxicity and bystander effect of 5-FU and 5′-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase, Br. J. Cancer 80 (1999) 1726-1733.
28. [28] Grem J.L., Mulcahy R.T., Miller E.M., Allegra C.J., Fischer P.H., Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line, Biochem. Pharmacol. 38 (1989) 51-59.
29. [29] Schwartz E.L., Baptiste N., Megati S., Wadler S., Otter B.A., 5-Ethoxy-2′-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression, Cancer Res. 55 (1995) 3543-3550.
30. [30] Zimmerman M., Seidenberg J., Deoxyribosyl Transfer. I. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues, J. Biol. Chem. 239 (1964) 2618-2621.
31. [31] Yoshimura A., Kuwazaru Y., Furukawa T., Yoshida H., Yamada K., Akiyama S., Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors, Biochim. Biophys. Acta. 1034 (1990) 107-113.
32. [32] Lionetti F.J., Fortier N.L., Metabolism of deoxyinosine by human erythrocyte ghosts, Biochim. Biophys. Acta. 119 (1966) 462-469.
33. [33] Szabados E., Duggleby R.G., Christopherson R.I., Metabolism of adenosine and deoxyadenosine by human erythrocytes and CCRF-CEM leukemia cells, Int. J. Biochem. Cell Biol. 28 (1996) 1405-1415.
34. [34] Pogolotti A.L., Nolan P.A., Santi D.V., Methods for the complete analysis of 5-fluorouracil metabolites in cell extracts, Anal. Biochem. 117 (1981) 178-186.